Basilea Pharmaceutica AG Share Price
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.10 CHF | -0.38% |
|
+0.39% | -4.94% |
| Market Cap | 648M 797M 698M 596M 1.12B 76.91B 1.14B 7.72B 3.02B 37.63B 2.99B 2.93B 130B | P/E 2026 * |
13.9x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 496M 610M 534M 456M 859M 58.84B 872M 5.91B 2.31B 28.79B 2.29B 2.24B 99.47B | EV / Sales 2026 * |
1.89x | EV / Sales 2027 * | 1.63x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -0.38% | ||
| 1 week | +0.39% | ||
| Current month | -2.62% | ||
| 1 month | +1.76% | ||
| 3 months | -3.53% | ||
| 6 months | -7.14% | ||
| Current year | -4.94% |
| 1 week | 50.4 |  | 52.7 |
| 1 month | 50.4 | | 56.3 |
| Current year | 47.8 | | 59.2 |
| 1 year | 44.7 | | 59.7 |
| 3 years | 32 | | 59.7 |
| 5 years | 29.55 | | 59.7 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 18/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 09/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 30/04/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 28/11/2011 |
| Chairman | 71 | 08/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 26/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/05/26 | Sell | -400 | 0.0030% | |||
| 13/05/26 | Sell | -1,043 | 0.0078% | |||
| 04/05/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.38% | +0.39% | -4.59% | +22.50% | 797M | |
| +1.64% | -5.39% | -4.63% | +12.09% | 46.06B | |
| -0.14% | -0.76% | +378.26% | +583.71% | 38.91B | |
| +0.39% | +2.79% | +8.23% | +61.99% | 35.57B | |
| -1.54% | -4.01% | +5.95% | -13.03% | 33.13B | |
| -0.87% | -3.19% | -1.27% | +29.16% | 26.42B | |
| -1.28% | -6.20% | - | - | 16.61B | |
| -0.67% | -0.21% | +10.55% | +115.31% | 15.08B | |
| -6.72% | -5.32% | +3.85% | +7.52% | 14.08B | |
| +0.40% | -2.79% | +3.58% | -31.98% | 12.81B | |
| Average | -0.90% | -2.04% | +44.44% | +87.47% | 23.95B | |
| Weighted average by Cap. | -0.44% | -2.59% | +68.28% | +122.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 263M 323M 283M 242M 455M 31.19B 462M 3.13B 1.23B 15.26B 1.21B 1.19B 52.72B | 267M 329M 288M 246M 463M 31.73B 470M 3.19B 1.25B 15.53B 1.23B 1.21B 53.63B |
| Net income | 51.57M 63.4M 55.55M 47.39M 89.29M 6.12B 90.61M 614M 240M 2.99B 238M 233M 10.34B | 39.24M 48.24M 42.27M 36.06M 67.95M 4.65B 68.95M 467M 183M 2.28B 181M 177M 7.87B |
| Net Debt | -152M -187M -164M -140M -264M -18.06B -268M -1.81B -710M -8.84B -703M -688M -30.53B | -213M -261M -229M -195M -368M -25.22B -374M -2.53B -991M -12.34B -981M -960M -42.63B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | CHF 52.00 | -0.57% | 2,494 |
| 22/07/26 | CHF 52.30 | -0.19% | 17,109 |
| 21/07/26 | CHF 52.40 | +1.75% | 16,403 |
| 20/07/26 | CHF 51.50 | -0.58% | 13,778 |
| 17/07/26 | CHF 51.80 | 0.00% | 32,009 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
